What Is CJC-1295 + Ipamorelin? Mechanism and Preclinical Research Summary

At a glance: CJC-1295 + Ipamorelin summary

CJC-1295 + Ipamorelin combines two distinct growth hormone secretagogues to evaluate dual-pathway activation of the anterior pituitary gland.

CJC-1295 acts as a GHRH analog, while Ipamorelin functions as a selective growth hormone secretagogue receptor (GHSR-1a) agonist.

Preclinical studies demonstrate that co-administering these compounds produces a synergistic release of endogenous growth hormone without significantly altering cortisol or prolactin levels.

In laboratory models, this peptide blend is frequently utilized to examine musculoskeletal remodeling, nitrogen retention, and cellular tissue repair mechanisms.

Principal investigators can review batch purity across our catalog of research peptides or directly access the CJC-1295 No DAC + Ipamorelin 10mg blend for laboratory assays.

What is CJC-1295? GHRH receptor target and mechanism

CJC-1295 is a synthetic 29-amino acid peptide analog of growth-hormone-releasing hormone (GHRH). As a GHRH analog, it targets and binds to the GHRH receptor located on somatotroph cells in the anterior pituitary gland, signaling the transcription and secretion of growth hormone (GH).

In preclinical models, CJC-1295 was engineered to overcome the rapid enzymatic degradation characteristic of native GHRH (1-29) by resisting dipeptidyl peptidase-4 (DPP-4) cleavage.

Studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research, CJC-1295 enables laboratories to evaluate extended somatotroph activation without inducing rapid receptor desensitization.

To explore individual secretagogue dynamics, researchers can review comparative data in our dedicated CJC-1295 and Ipamorelin research portal.

What is Ipamorelin? Selective GHRP and ghrelin receptor agonist

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) classified as a growth hormone secretagogue and selective ghrelin receptor agonist. It binds with high affinity to the growth hormone secretagogue receptor (GHSR-1a) present on pituitary somatotrophs and hypothalamic neurons.

Unlike earlier growth hormone releasing peptides such as GHRP-2 or GHRP-6, preclinical assays show that Ipamorelin possesses superior receptor selectivity. It stimulates GH secretion without triggering secondary elevations of adrenocorticotropic hormone (ACTH), cortisol, or prolactin.

In animal models, Ipamorelin induces natural pulsatile growth hormone release that closely mimics physiological baseline spikes. Investigators analyzing single-agent secretagogue kinetics frequently utilize single-peptide controls such as Ipamorelin 5mg vials.

Why are CJC-1295 and Ipamorelin studied together in research models?

The co-formulation of CJC-1295 and Ipamorelin represents one of the most widely cited dual-peptide paradigms in neuroendocrine research. Rather than utilizing a single signal pathway, the combination simultaneously targets two independent, complementary receptors on pituitary somatotrophs.

CJC-1295 activates the GHRH receptor pathway, stimulating cyclic adenosine monophosphate (cAMP) production. Simultaneously, Ipamorelin activates the GHSR-1a pathway, stimulating intracellular calcium release via phospholipase C (PLC) signaling.

In vitro and animal models demonstrate that activating both signaling cascades concurrently yields a synergistic release of growth hormone that exceeds the additive effect of either peptide administered in isolation. Laboratories studying these synergistic signaling cascades can source standardized 10mg CJC-1295 No DAC + Ipamorelin vials.

How does the CJC-1295 + Ipamorelin blend influence GH and downstream IGF-1?

When somatotrophs release growth hormone into systemic circulation during animal models, GH binds to transmembrane growth hormone receptors primarily located in hepatic tissue. This receptor engagement activates the JAK/STAT signal transduction pathway, stimulating the expression and release of Insulin-like Growth Factor 1 (IGF-1).

IGF-1 acts as the principal secondary mediator responsible for cellular hypertrophy, extracellular matrix synthesis, and satellite cell activation in musculoskeletal and connective tissues.

By maintaining physiological, pulsatile growth hormone output, the CJC-1295 + Ipamorelin combination provides researchers with a controlled framework to monitor downstream IGF-1 elevations over extended experimental timeframes.

What preclinical research models utilize CJC-1295 + Ipamorelin?

In vitro and animal research models utilize the CJC-1295 + Ipamorelin blend across several distinct research domains:

1. Connective Tissue and Tendon Repair: Assessing collagen synthesis, tenocyte proliferation, and microstructural matrix recovery following induced tendinopathy or ligamental strain.

2. Skeletal Muscle Anabolism: Evaluating nitrogen retention, satellite cell activation, and protein deposition rates in catabolic or aging rodent models.

3. Bone Mineralization: Monitoring osteoblast activity, cortical bone density, and microarchitectural repair in fracture models.

4. Metabolic Substrate Utilization: Examining lipolysis mechanisms and visceral lipid oxidation during nutrient partitioning experiments.

Researchers building comparative endocrine protocols can examine broader technical frameworks in our peptide research library.

CJC-1295 No DAC vs CJC-1295 DAC: Crucial structural distinctions

A critical consideration in study design is distinguishing between CJC-1295 No DAC (Modified GRF 1-29) and CJC-1295 DAC.

CJC-1295 No DAC lacks the Drug Affinity Complex linker, resulting in a half-life of approximately 30 minutes in rodent models. This short half-life enables discrete, natural pulsatile GH release, making it the ideal component to blend with Ipamorelin.

CJC-1295 DAC contains a reactive maleimidopropionic acid linker that covalently binds to serum albumin in circulation, extending its half-life to several days and producing continuous baseline GH elevation. For assays specifically evaluating extended GHRH receptor occupancy, investigators can examine CJC-1295 DAC 5mg.

How to vet a research peptide supplier: Red flags vs gold standards

Procuring research peptides for quantitative assays requires rigorous vendor screening to eliminate experimental variables caused by degradation, impurities, or mislabeling.

Red Flags to Avoid: Suppliers that fail to publish lot-specific COAs, vendors relying solely on generic HPLC reports without Mass Spectrometry identity verification, absence of endotoxin data, lack of US-based fulfillment, or websites making illegal human dosing claims.

Gold Standards to Demand: High-Performance Liquid Chromatography (HPLC) showing >99% purity, Mass Spectrometry (MS) confirming exact molecular mass, Limulus Amebocyte Lysate (LAL) testing guaranteeing low endotoxins (<0.01 EU/mg), and transparent US synthesis and fulfillment.

Evaluating vendor criteria for peptide blends

When purchasing multi-compound blends, laboratories must evaluate vendors against six verifiable criteria:

1. Purity Verification: HPLC chromatograms must show >99.0% combined purity with clear separation of both peptide peaks and zero TFA salt interference.

2. Identity Mass Match: Mass Spectrometry must confirm the precise molecular weights for CJC-1295 No DAC (MW: ~3357.9 g/mol) and Ipamorelin (MW: ~711.9 g/mol).

3. Lot Traceability: Every vial label must display an indelible lot number matching a publicly accessible third-party COA.

4. Endotoxin Limits: LAL assay confirmation verifying endotoxin content well below toxicity thresholds for cellular assays.

5. Storage & Packaging: Lyophilization under inert nitrogen atmosphere and temperature-controlled storage at -20°C prior to dispatch.

6. Express Domestic Transit: Rapid shipping options with thermal insulation to safeguard product integrity.

Related growth hormone secretagogues in research

To conduct comparative secretagogue studies, laboratories frequently analyze CJC-1295 + Ipamorelin against other growth hormone axis modulators:

Tesamorelin: A stabilized GHRH analog with high affinity for GHRH receptors, evaluated primarily in metabolic and lipodystrophy research models. Examine specifications for Tesamorelin 10mg.

Sermorelin: An abbreviated 29-amino acid GHRH fragment used to establish baseline endogenous GHRH receptor sensitivity.

GHRP-2 and GHRP-6: Earlier-generation ghrelin agonists utilized to contrast selective vs. non-selective pituitary receptor pathways.

For large-scale screening projects or institutional purchasing across multiple compound classes, research teams can submit requests through our wholesale inquiry portal.

Ordering CJC-1295 + Ipamorelin from PX1 Research

When sourcing research material from PX1 Research, your laboratory receives analytical-grade, lyophilized powder manufactured under strict quality controls. Our 10mg blend vials contain a precise 1:1 formulation of 5mg CJC-1295 No DAC and 5mg Ipamorelin, sealed under inert gas to prevent oxidation.

Orders placed prior to 3:00 PM EST (Monday through Friday) ship the same day from our temperature-controlled centers in California and Arizona via tracked domestic carriers. Every batch provides immediate access to downloadable COAs verifying HPLC purity, MS identity, and endotoxin metrics.

Our customer support team is available to assist research personnel with lot validation, technical documentation, and supply logistics. Secure high-purity compounds for your lab by choosing to order 10 mg vials of CJC-1295 + Ipamorelin blend directly from PX1 Research.